BlackRock Fund Advisors’s Enzo Biochem, Inc. ENZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$8.91M Buy
1,284,014
+177,486
+16% +$1.13M ﹤0.01% 2638
2016
Q3
$5.63M Buy
1,106,528
+75,755
+7% +$452K ﹤0.01% 2791
2016
Q2
$6.15M Buy
1,030,773
+942,472
+1,067% +$5.23M ﹤0.01% 2680
2016
Q1
$402K Sell
88,301
-6,574
-7% -$29.3K ﹤0.01% 3270
2015
Q4
$427K Buy
94,875
+4,447
+5% +$18.8K ﹤0.01% 3304
2015
Q3
$287K Sell
90,428
-14,453
-14% -$43.9K ﹤0.01% 3358
2015
Q2
$318K Sell
104,881
-901,698
-90% -$2.53M ﹤0.01% 3342
2015
Q1
$2.97M Buy
1,006,579
+19,748
+2% +$64.7K ﹤0.01% 3044
2014
Q4
$4.38M Buy
986,831
+165,238
+20% +$788K ﹤0.01% 2946
2014
Q3
$4.23M Sell
821,593
-34,423
-4% -$184K ﹤0.01% 2847
2014
Q2
$4.49M Buy
856,016
+754,282
+741% +$3.26M ﹤0.01% 2898
2014
Q1
$423K Buy
101,734
+453
+0.4% +$1.55K ﹤0.01% 3275
2013
Q4
$296K Buy
101,281
+4,230
+4% +$10.5K ﹤0.01% 3321
2013
Q3
$245K Buy
97,051
+7,560
+8% +$17.9K ﹤0.01% 3326
2013
Q2
$186K Buy
+89,491
New +$198K ﹤0.01% 3348

Other funds holding ENZ

BlackRock Fund Advisors's ENZ Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Enzo Biochem, Inc. (ENZ) stake by 16% in Q4 2016, buying an estimated $1.13M and bringing the position to 1,284,014 shares worth $8.91M. The position accounts for ﹤0.01% of the portfolio, ranked #2638.

BlackRock Fund Advisors first reported a position in ENZ in Q2 2013 and has held it in 15 quarters since. 109 funds tracked by Wall St. Rank hold ENZ as of Q4 2016.

  • BlackRock Fund Advisors held 1,284,014 shares of Enzo Biochem, Inc. worth $8.91M as of Q4 2016.
  • BlackRock Fund Advisors bought 177,486 Enzo Biochem, Inc. shares in Q4 2016, an estimated $1.13M.
  • Enzo Biochem, Inc. made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2638 holding.
  • BlackRock Fund Advisors first reported a position in Enzo Biochem, Inc. in Q2 2013 and has held it in 15 quarters since.
  • 109 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.